PSA nadir as predictor of overall survival in hormone-sensitive metastatic prostate cancer

PSA nadir as predictor of overall survival in hormone-sensitive metastatic prostate cancer

Dayana Sáenz-Rengifo 1 , Iván D. Patiño 2 , Byron López-Mesa 2 , Rodolfo Varela-Ramírez 2

1 Servicio de Urología, Universidad Nacional de Colombia, Bogotá, Colombia; 2 Servicio de Urología Oncológica, Instituto Nacional de Cancerología, Bogotá, Colombia

*Correspondence: Iván D. Patiño. Email: ivan.patino.md@gmail.com

Abstract

Objective: Androgen deprivation therapy, along with prostate-specific antigen (PSA), is used to monitor the progression of prostate cancer. This study evaluates the relationship between the PSA nadir and overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with orchiectomy.

Method: Retrospective cohort of 220 patients with mCRPC managed with orchiectomy.

Results: A PSA nadir ≥ 0.2 ng/ml and time to nadir > 6 months are significant predictors of overall survival.

Conclusions: PSA nadir is a useful tool as a predictor of overall survival in patients with mCRPC.

Keywords: Prostate neoplasms. Prostate-specific antigen. Metastasis. Survival.

Contents

This content is only available in Spanish.
⇄ Versión en Español
DOI not available
Add to Mendeley

This content is only available in Spanish.

    PERMANYER

    Mallorca, 310
    08037 Barcelona (España)

    Arquímedes, 190 – Colonia Polanco
    Delegación Miguel Hidalgo
    11560 Ciudad de México (México)

    RECURRING LINKS
    CLOCKSS is a dak archive that ensures the long-term survival of web-based scholary publications, governed by and for its stakeholders.

    This journal adheres to the principles established by the Committee on Publication Ethics

    English versión
    DOI not available

    Editorial times

    The editorial process consists of 6 stages:

    1. Reception of the manuscript (indeterminate, depending on whether the author meets the requirements): its objective is to verify that the manuscript complies with the specifications of these instructions for authors and that the submitted documentation is complete.

    2. Initial editorial review (maximum 5 business days): its objective is to corroborate the relevance, timeliness, originality, and scientific contribution of the manuscript, as well as the methodological and statistical soundness of the study. At this time, it will be submitted to an electronic plagiarism detection system. Derived from this, a rejected opinion may be obtained, or it will be sent for review by peer researchers.

    3. Review by peer researchers (maximum 30 business days): the opinion of at least two experts in the area in question will be obtained, who will evaluate the technical and methodological aspects of the investigation.

    4. Editorial review (maximum 7 business days): its objective is to make a decision based on the opinion of peer reviewers. The opinion can be rejected, major changes, minor changes or accepted. In the case of major or minor changes, it will be submitted again for evaluation by the initial peer reviewers.

    5. Final edition (6 weeks): its objective is the technical and linguistic edition (and translation), layout of galleys, DOI assignment, and correction by the author.

    6. Advanced publication: All manuscripts will be published ahead of print on the journal’s website as soon as they complete the editing process, until they are incorporated into a final issue of the journal.